Drug Response Testing and Repurposing Using Glioblastoma Organoid

The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.

NCT Number	NCT06782984
Lead Sponsor	Chungnam National University Hospital Collaborators: Korea Advanced Institute of Science and Technology, Keimyung University Dongsan Medical Center, Soonchunhyang University Hospital, Dong-A University Hospital, Yeungnam University Hospital
Conditions	Glioblastoma, Organoid
Enrollment	150 participants
Start Date	2021-08-18
Primary Completion	2028-12 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2025-01-20